Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The status of tumor mutational burden and immunotherapy

28 Jun 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35764740
DOI: 10.1038/s43018-022-00382-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The status of tumor mutational burden and immunotherapyPMID 35764740Read ↗

Tumor mutational burden and immunotherapy in gliomasSemantic proximity Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

Mutational and Antigenic Landscape in Tumor Progression and Cancer ImmunotherapySemantic proximity Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSemantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.Semantic proximity Read ↗

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.Semantic proximity Read ↗

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read ↗

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.